阿诺医药 ANL 深 沪
等待开盘 01-31 09:30:00 美东时间
9.66
+3.130
+47.93%
华盛通- 最 高10.10
- 今 开9.12
- 成交量 667.56万股
- 最 低 6.58
- 昨 收 6.53
- 总市值 3.56亿
- 52周最高 10.10
- 市盈率 静 --
- 换手率 18.09%
- 52周最低 0.8786
- 委 比 97.27%
- 总股本 3690.03万
- 历史最高 19.2999
- 量 比 3.38
- 振 幅 53.91%
- 历史最低 0.8786
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 矽晶电信飙升近30%，Q4营收同比大增17%；西南航空大涨18%
矽晶电信飙升近30%，Q4营收同比大增17%；摩丁制造大涨20%，分拆技术业务并与Gentherm合并，以优化公司结构；西南航空大涨18%，Q4每股收益及全年指引均超预期>>
01-30 18:27
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye与ASK Pharm签署AN9025独家许可协议，授权其在 mainland China, Hong Kong, and Macau 开发、生产和商业化。Adlai Nortye将保留全球权利，预计获得高达16亿元人民币的总付款，包括首付款、里程碑付款及销售分成。AN9025是潜在同类最佳的pan-RAS(ON)抑制剂，针对多种肿瘤类型的RAS突变，预计2026年Q1启动I期临床试验。此次合作旨在加速RAS突变癌症患者的治疗开发。
2025-12-29 11:00
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has provided an announcement. Adlai ...
2025-12-03 19:27
Adlai Nortye to Participate in Upcoming Investor Conferences
Adlai Nortye Ltd. announced that its management team will participate in two upcoming investor conferences: the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Coral Gables, Florida, and the 36th Oppenheimer Annual Healthcare Life Sciences Conference on February 25-26, 2026. The company, focused on innovative cancer therapies, is developing therapies in two key areas: next-generation cancer immunotherapies and RAS-targeting ther...
2025-11-21 13:00
Adlai Nortye Ltd. Plans Redomiciliation to Singapore
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) just unveiled an announcement. Adlai...
2025-10-23 05:28
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Adlai Nortye Ltd. will present AN4035, a novel CEACAM5-targeting antibody drug conjugate (ADC) with a proprietary pan-RAS(ON) inhibitor payload, at the AACR-NCI-EORTC conference. AN4035 demonstrates strong intracellular retention, potent cytotoxicity in CEACAM5-positive/RAS-addicted cancers, and a favorable toxicology profile. The Company highlights its potential to overcome limitations of existing pan-RAS(ON) inhibitors by targeting tumors speci...
2025-10-22 04:00
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Adlai Nortye Ltd. will present AN4035, a novel CEACAM5-targeting antibody-drug conjugate (ADC) with a pan-RAS(ON) inhibitor payload, at the AACR-NCI-EORTC conference on October 25, 2025. The presentation will discuss the therapeutic potential and design of AN4035 to broaden the treatment window for cancer patients. The company focuses on innovative cancer therapies, including RAS-targeted treatments, and plans to share further details following t...
2025-10-14 03:07
HC Wainwright & Co. Downgrades Adlai Nortye to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades Adlai Nortye (NASDAQ:ANL) from Buy to Neutral.
2025-06-03 00:07
派格生物上市：14年长期陪伴，联想之星斩获一个明星IPO
在医疗健康领域，联想之星已经收获了6个明星IPO。 作者丨簪竹 来源丨投中网 陪伴14年后，联想之星收获了一个明星IPO。 5月27日，派格生物成功在港上...
2025-05-27 10:21
